Ergoteles’s Madrigal Pharmaceuticals MDGL Stock Holding History

Ergoteles’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-8,398	Closed	-$2.03M	–	1306
2023 Q1	$2.03M	Buy	8,398 +6,359	+312%	+$1.73M	0.08%	268
2022 Q4	$592K	Buy	+2,039	New	+$199K	0.02%	638
2022 Q1	–	Sell	-10,428	Closed	-$884K	–	1470
2021 Q4	$884K	Buy	10,428 +4,338	+71%	+$356K	0.03%	453
2021 Q3	$486K	Buy	+6,090	New	+$526K	0.02%	593

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Ergoteles's MDGL Position: Q2 2023 in Review

Ergoteles sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2023, closing a stake of 8,398 shares — an estimated $2.03M sold.

Ergoteles first reported a position in MDGL in Q3 2021 and held it in 4 quarters. The position peaked at $2.03M in Q1 2023. 208 funds tracked by Wall St. Rank hold MDGL as of Q2 2023.

Ergoteles reported no remaining Madrigal Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Ergoteles sold 8,398 Madrigal Pharmaceuticals shares in Q2 2023, an estimated $2.03M.
Ergoteles first reported a position in Madrigal Pharmaceuticals in Q3 2021 and held it in 4 quarters.
Ergoteles's Madrigal Pharmaceuticals position peaked at $2.03M in Q1 2023.
208 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.